Latest Content
Mar 20 - 2024
Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements and a notable IPO. This revival, though less conspicuous than obesity’s, emerges from years of underinvestment, resulting in a landscape filled...
Read More
Feb 23 - 2024
Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma:
Pfizer acquired Seagen for $43 billion
AbbVie invested over $10 billion in ImmunoGen
Merck committed $4 billion upfront, with a potential total...
Read More
Feb 12 - 2024
In 2023, the digital health ecosystem witnessed notable consolidation, increased investor scrutiny and a decline in investor support. Health systems prioritised operational efficiency and big tech made strategic investments in emerging AI capabilities.
This...
Read More
No posts found
More content
Loading...